News
LMMY
0.302
NaN%
--
*LAMY Completes Strategic Acquisition Of Cancer Therapy Innovator Exousia AI, Inc. >LMMY
Dow Jones · 12/02 15:28
LAMY 10-K
Press release · 10/18 09:50
Weekly Report: what happened at LMMY last week (0908-0912)?
Weekly Report · 09/15 12:28
Weekly Report: what happened at LMMY last week (0901-0905)?
Weekly Report · 09/08 12:30
Weekly Report: what happened at LMMY last week (0825-0829)?
Weekly Report · 09/01 12:23
Weekly Report: what happened at LMMY last week (0818-0822)?
Weekly Report · 08/25 12:40
Weekly Report: what happened at LMMY last week (0811-0815)?
Weekly Report · 08/18 12:27
Weekly Report: what happened at LMMY last week (0804-0808)?
Weekly Report · 08/11 12:40
Weekly Report: what happened at LMMY last week (0728-0801)?
Weekly Report · 08/04 12:43
Weekly Report: what happened at LMMY last week (0721-0725)?
Weekly Report · 07/28 12:43
Weekly Report: what happened at LMMY last week (0714-0718)?
Weekly Report · 07/21 12:29
Weekly Report: what happened at LMMY last week (0707-0711)?
Weekly Report · 07/14 12:44
Weekly Report: what happened at LMMY last week (0630-0704)?
Weekly Report · 07/07 12:29
Weekly Report: what happened at LMMY last week (0623-0627)?
Weekly Report · 06/30 12:40
Weekly Report: what happened at LMMY last week (0616-0620)?
Weekly Report · 06/23 12:28
Weekly Report: what happened at LMMY last week (0609-0613)?
Weekly Report · 06/16 12:39
Weekly Report: what happened at LMMY last week (0602-0606)?
Weekly Report · 06/09 12:41
Weekly Report: what happened at LMMY last week (0526-0530)?
Weekly Report · 06/02 12:55
Weekly Report: what happened at LMMY last week (0519-0523)?
Weekly Report · 05/26 12:53
Weekly Report: what happened at LMMY last week (0512-0516)?
Weekly Report · 05/19 12:38
More
Webull provides a variety of real-time LMMY stock news. You can receive the latest news about L A M Y through multiple platforms. This information may help you make smarter investment decisions.
About LMMY
LAMY is a clinical stage biotechnology company. The Company is engaged in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with genetic functionality, capable of selectively targeting specific cells to address diseases with unmet medical needs. The engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. Its proprietary manufacturing process utilizes plant-based materials to create exosomes used in various commercial applications, including dermatology and dentistry.